Zoetis (ZTS) Payables (2012 - 2026)
Zoetis' (ZTS) quarterly Payables came in at $731.0 million in Q1 2026, up 13.51% year-on-year from $644.0 million in Q1 2025, and up 7.98% on a QoQ basis from $677.0 million in Q4 2025.
Zoetis (ZTS) Payables (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Payables data on file, last reported at $731.0 million in Q1 2026.
- On a quarterly basis, Payables rose 13.51% year-over-year to $731.0 million in Q1 2026; TTM through Mar 2026 was $731.0 million, a 13.51% increase from a year earlier, with the FY2025 full-year figure at $677.0 million, up 3.04% from the prior year.
- Payables for Q1 2026 stood at $731.0 million, up from $677.0 million in the prior quarter.
- Over the last five years, Payables for ZTS reached as high as $731.0 million in Q1 2026 and fell as low as $376.0 million in Q3 2022.
- Historically, Payables has averaged $578.6 million across 5 years, with a median of $612.0 million in 2023.
- Across the five-year window, Payables increased 18.9% in 2022 and retreated 3.44% in 2024, its largest moves.
- Year by year, Payables stood at $581.0 million in 2022, then climbed by 5.34% to $612.0 million in 2023, then rose by 7.35% to $657.0 million in 2024, then climbed by 3.04% to $677.0 million in 2025, then grew by 7.98% to $731.0 million in 2026.
- Per Business Quant data, the three most recent Payables figures were $731.0 million in Q1 2026, $677.0 million in Q4 2025, and $410.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 4.96 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 2.60 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 731.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 3.13 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 498.30 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 731,000.00 |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.75 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 773.00 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 372.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 58.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 731.00 Mn |
| Dec 31, 2025 | 677.00 Mn |
| Sep 30, 2025 | 410.00 Mn |
| Jun 30, 2025 | 730.00 Mn |
| Mar 31, 2025 | 644.00 Mn |
| Dec 31, 2024 | 657.00 Mn |
| Sep 30, 2024 | 404.00 Mn |
| Jun 30, 2024 | 617.00 Mn |
| Mar 31, 2024 | 627.00 Mn |
| Dec 31, 2023 | 612.00 Mn |
| Sep 30, 2023 | 390.00 Mn |
| Jun 30, 2023 | 639.00 Mn |
| Mar 31, 2023 | 601.00 Mn |
| Dec 31, 2022 | 581.00 Mn |
| Sep 30, 2022 | 376.00 Mn |
| Jun 30, 2022 | 585.00 Mn |
| Mar 31, 2022 | 555.00 Mn |
| Dec 31, 2021 | 590.00 Mn |
| Sep 30, 2021 | 387.00 Mn |
| Jun 30, 2021 | 492.00 Mn |